publication date: May. 9, 2014


By Paul Goldberg

Brian Druker has some awesome jobs to fill.

As many as 30 scientists and their teams will get to focus on cancer research without having to worry about applying for grants.

“It’s about bringing 20 to 30 people together, giving them sufficient funding—almost like [Howard Hughes Medical Institute] level funding,” Druker said to The Cancer Letter. “If you have 20 to 30 people who are focused on science, working as a team to solve a problem, judged on progress toward the goal, as opposed to how many grants and publications do you have, we think we can make a more rapid contribution in this area.

“And, in addition, if 20 or 30 people are spending their time focused on science, that’s like 40 to 60 people in a regular research environment, because they have their administrative responsibilities, their teaching responsibilities, and their grant-writing responsibilities.”

The new goal is a logical continuation of Druker’s work with Gleevec (imatinib), a spectacularly effective treatment for chronic myelogenous leukemia and several other cancers.

The difference, of course, is that Druker, director of the Knight Cancer Institute at Oregon Health & Science University, and a member of the small club of people whose work has revolutionalized cancer therapy, wants to move identification of cancer’s lethal characteristics to an earlier stage in the disease process.

The research program Druker envisions will require $1 billion, of which $300 million is already on hand, and $200 million more will … Continue reading 40-19 Oregon Center Launching $1 Billion Program

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.